Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature

Recent evidence suggests that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors significantly improve progression-free survival and overall survival among metastatic breast cancer patients. However, given the effects on cell cycle arrest, there is potential for CDK4/6 inhibitors and radiotherapy (RT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Franco, Rejane, Cao, Jeffrey Q., Yassa, Michael, Hijal, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297034/
https://www.ncbi.nlm.nih.gov/pubmed/37366898
http://dx.doi.org/10.3390/curroncol30060415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297034/
https://www.ncbi.nlm.nih.gov/pubmed/37366898
http://dx.doi.org/10.3390/curroncol30060415

Ejemplares similares